Lpl Financial LLC Cytom X Therapeutics, Inc. Transaction History

Lpl Financial LLC

$218 Billion
Q3 2024

A detailed history of Lpl Financial LLC transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 38,315 shares of CTMX stock, worth $40,613. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,315

Previous 36,315 5.51%

Holding current value

$40,613

Previous $44,000 2.27%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	BUY	$1.12 - $1.51 $2,240 - $3,020	2,000 Added 5.51%	38,315 $45,000
Q2 2024 Aug 07, 2024	SELL	$1.21 - $5.13 $67,760 - $287,280	-56,000 Reduced 60.66%	36,315 $44,000
Q1 2024 May 10, 2024	SELL	$1.41 - $2.74 $25,309 - $49,183	-17,950 Reduced 16.28%	92,315 $201,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $1.55 $5,214 - $7,553	4,873 Added 4.62%	110,265 $170,000
Q3 2023 Nov 13, 2023	BUY	$1.26 - $1.87 $8,980 - $13,327	7,127 Added 7.25%	105,392 $135,000
Q2 2023 Jul 31, 2023	BUY	$1.41 - $1.92 $55,695 - $75,840	39,500 Added 67.22%	98,265 $169,000
Q4 2022 Feb 07, 2023	BUY	$1.19 - $1.91 $3,570 - $5,730	3,000 Added 5.38%	58,765 $94,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $25,860 - $41,419	21,025 Added 60.52%	55,765 $81,000
Q2 2022 Aug 12, 2022	BUY	$1.53 - $2.89 $53,152 - $100,398	34,740 New	34,740 $64,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $73,820 - $140,964	-19,075 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $44,604 - $66,389	-10,325 Reduced 35.12%	19,075 $97,000
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $41,145 - $64,415	6,500 Added 28.38%	29,400 $186,000
Q1 2021 May 14, 2021	BUY	$6.6 - $9.0 $151,140 - $206,100	22,900 New	22,900 $177,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.

Account

Lpl Financial LLC Cytom X Therapeutics, Inc. Transaction History